BIAF
BEARISHAt a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
AI-powered fundamental assessment
Key Strengths
Key Risks
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Ref P/E, PEG, Graham Number
- Price/Book of 0.52 may suggest asset-based floor
- Price/Sales of 0.90 below sector average
- No earnings to support valuation (P/E N/A, Forward P/E -2.25)
- No Graham Number or Intrinsic Value available
Ref Growth rates
- Most recent Q/Q EPS growth of +7.1% shows minor improvement
- Revenue Growth (YoY): -38.50%
- No analyst forecasts or target prices available
- No visibility on future earnings growth
Ref Historical trends
- 5Y price change: -99.5%
- 1Y price change: -92.9%
- History of large earnings misses
Ref Altman Z-Score, Piotroski F-Score
- Current Ratio of 3.65 indicates short-term liquidity
- Debt/Equity of 0.08 suggests low financial leverage
- Piotroski F-Score of 1/9 indicates severe financial weakness
- ROE of -245.18%, ROA of -71.71%
- No Altman Z-Score available, but financials suggest distress
Ref Yield, Payout
- No dividend paid
- Dividend Strength: 0/100
- Payout Ratio: 0.00%
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for BIAF and closest competitors.
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
BIAF
bioAffinity Technologies, Inc.
Primary
|
-99.5% | -98.4% | -92.9% | -86.5% | +9.8% | -1.5% |
|
QUCY
Mainz Biomed N.V.
Peer
|
-98.2% | -91.0% | -84.9% | -67.3% | -19.4% | +9.9% |
|
SNYR
Synergy CHC Corp.
Peer
|
-94.2% | -94.2% | -78.9% | -80.5% | -60.5% | -8.7% |
|
CANF
Can-Fite BioPharma Ltd.
Peer
|
-99.4% | -91.8% | -87.6% | -68.4% | -9.9% | -4.3% |
|
XTLB
XTL Biopharmaceuticals Ltd.
Peer
|
-81.5% | -49.8% | -49.8% | -50.6% | -5.8% | -1.2% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability
Profit margins and return metrics
Growth
Revenue and earnings growth rates
Financial Health
Balance sheet strength and liquidity metrics
Quarterly Earnings History
EPS performance vs analyst estimates
Healthcare Sector Comparison
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
BIAF
bioAffinity Technologies, Inc.
|
BEARISH | $6.07M | - | -245.2% | -217.5% | $1.35 | |
|
QUCY
Mainz Biomed N.V.
|
BEARISH | $6.09M | - | -488.3% | -% | $0.49 | Compare |
|
SNYR
Synergy CHC Corp.
|
BEARISH | $5.93M | - | -% | -40.6% | $0.52 | Compare |
|
CANF
Can-Fite BioPharma Ltd.
|
BEARISH | $6.23M | - | -178.2% | -% | $2.91 | Compare |
|
XTLB
XTL Biopharmaceuticals Ltd.
|
BEARISH | $5.78M | - | -577.1% | -% | $2.44 | Compare |
Past News Coverage
Recent headlines mentioning BIAF from our newsroom.